// App-Quantinova.ai

6017 : Preliminary results for the advanced salivary gland carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.

Researchers

Presenter

  • Roger B. Cohen

Principal Investigators

  • Jean-Pierre Delord

  • Toshihiko Doi

  • Sarina Anne Piha-Paul

  • Stephen V. Liu

  • Jill Gilbert

  • Alain Patrick Algazi

  • Sara Cresta

  • Ruey-Long Hong

  • Christophe Le Tourneau

  • Daphne Day

  • Andrea Varga

  • Elena Elez

  • John M. Wallmark

  • Sanatan Saraf

  • Anne Morosky

  • Jonathan D. Cheng

  • Bhumsuk Keam

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • Institut Claudius Regaud, Toulouse, France

  • National Cancer Center Hospital, Tokyo, Japan

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Georgetown University, Washington, DC

  • Vanderbilt University School of Medicine, Nashville, TN

  • University of California, San Francisco, San Francisco, CA

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Institut Curie, Paris Cedex, France

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Gustave Roussy, Villejuif, France

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Maryland Oncology Hematology PA, Rockville, MD

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • Canada

  • Taiwan

  • Japan

  • Italy

  • Spain

  • United States

  • France

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Salivary gland cancer

  • Sarcoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • Unknown

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02054806

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved